Open AccessCarbimazole-induced cholestatic hepatitis in Graves′ disease
Author(s) -
Sunil Kumar Kota,
Lalit Kumar Meher,
Siva Krishna Kota,
Sruti Jammula,
Kirtikumar D Modi
Publication year - 2013
Publication title -
indian journal of endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.456
H-Index - 28
eISSN - 2230-9500
pISSN - 2230-8210
DOI - 10.4103/2230-8210.109660
Subject(s) - carbimazole , medicine , granulocytosis , jaundice , hepatitis , disease , graves' disease , pediatrics , pregnancy , drug , side effect (computer science) , dermatology , gastroenterology , pharmacology , granulocyte , biology , computer science , genetics , programming language
Antithyroid medications are one of the treatment options for Graves' disease. Carbimazole is widely used as the drug of choice, except in pregnancy, where propythiouracil is preferred by many. It is generally well-tolerated. Its side-effects include allergy, upper gastrointestinal upset, a rare occurrence of granulocytosis, and others. Hepatitis is another rare, but serious side-effect. We report a healthy 30-year-old male patient with Graves' disease, who developed cholestatic jaundice after Carbimazole therapy for four months. He made a full recovery after the drug was discontinued. An idiosyncratic mechanism seemed likely.